Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

医学 前列腺癌 内科学 紫杉烷 肿瘤科 癌症 不利影响 谷氨酸羧肽酶Ⅱ 泌尿科 乳腺癌
作者
Scott T. Tagawa,Charlene Thomas,Oliver Sartor,Michael Sun,Judith Stangl‐Kremser,Mahelia Bissassar,Shankar Vallabhajosula,Sandra Huicochea Castellanos,Jones T. Nauseef,Cora N. Sternberg,Ana M. Molina,Karla V. Ballman,David M. Nanus,Joseph R. Osborne,Neil H. Bander
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (7): 842-851 被引量:67
标识
DOI:10.1200/jco.23.00573
摘要

PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225 Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225. METHODS Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225 Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D. RESULTS Radiochemistry and animal studies were favorable. Thirty-two patients received 225 Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%). CONCLUSION To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225 Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wydkyd发布了新的文献求助10
刚刚
JiaYu完成签到,获得积分10
1秒前
1秒前
纯情的阁的应助被嘻嘻哈哈采纳,获得310
2秒前
2秒前
Ava的应助被ghw采纳,获得10
3秒前
3秒前
英姑的应助被感动的芹菜采纳,获得10
4秒前
淡定沧海发布了新的文献求助10
4秒前
dimension完成签到,获得积分10
5秒前
ludwig完成签到,获得积分10
5秒前
清漪发布了新的文献求助10
5秒前
大个的应助被peekaboo采纳,获得10
6秒前
6秒前
科目三的应助被刘雨采纳,获得10
6秒前
7秒前
7秒前
medgreat发布了新的文献求助20
7秒前
方源的应助被QI采纳,获得30
7秒前
雷欣儿发布了新的文献求助10
7秒前
研友_enP05n完成签到,获得积分0
8秒前
LLk完成签到,获得积分10
8秒前
8秒前
体贴的哈密瓜完成签到 ,获得积分10
8秒前
9秒前
羊羊羊完成签到 ,获得积分10
10秒前
叽里呱啦发布了新的文献求助10
10秒前
Nobodyet完成签到,获得积分10
11秒前
斯文败类的应助被阿喔额采纳,获得10
11秒前
ding的应助被阿喔额采纳,获得10
11秒前
Leon完成签到,获得积分10
11秒前
烟花的应助被阿喔额采纳,获得10
11秒前
科研通AI2S的应助被阿喔额采纳,获得10
12秒前
12秒前
搜集达人的应助被阿喔额采纳,获得10
12秒前
张子贤发布了新的文献求助10
12秒前
研友_VZG7GZ的应助被阿喔额采纳,获得10
12秒前
无奈柚子发布了新的文献求助10
12秒前
lumu99发布了新的文献求助10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157735
求助须知:如何正确求助?哪些是违规求助? 9553703
关于积分的说明 21715617
捐赠科研通 7746969
什么是DOI,文献DOI怎么找? 3426878
关于科研通互助平台的介绍 2551593
邀请新用户注册赠送积分活动 2470900